soul trial semaglutide trial: Oral demonstrates a 14% reduction in risk of major adverse CV events SOUL: Oral Semaglutide Bests Usual
Description
Thank you Shipping was so quick and instructions were very clear
Non-genetic predictors of BMI loss We examined non-genetic factors that were predictive of GLP1 medication efficacy, as measured by the percentage change in BMI from baseline (BMI % )
Background Wegovy and Zepbound are both approved for weight loss but started as medications for type 2 diabetes
July 9, 2026 What Every Benefits Decision Maker Needs to Know If you sit on a benefits committee, approve vendor contracts, set plan design, or sign off on employee benefit programs, you are a fiduciary under ERISA
